Eyepoint, Inc. · NASDAQ:EYPT

Eyepoint — EyePoint Pharmaceuticals — Investor Presentation (July 2025)

26 slides from Eyepoint's investor presentation, Jul 29, 2025

  1. Slide 1: Investor Presentation July 2025

    Investor Presentation July 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.2

  2. Slide 2: Legal Disclaimers

    Legal Disclaimers ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate

  3. Slide 3: The Leader in Sustained Release Drug Delivery for Retinal Disease

    The Leader in Sustained Release Drug Delivery for Retinal Disease ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Compelling efficacy and safety data in DME from VERONA Phase 2 trial; positive EOP2 meeting with FDA $318M at 3/31/25 – runway into 2027 post Phase 3 pivotal data in 2026 DURAV

  4. Slide 4: Pipeline Leveraging Bioerodible Durasert E Drug Delivery Technology

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. wet AMD, wet age-related macular degeneration; DME, diabetic macular edema; EOP2, End-of-Phase 2; PK, pharmacokinetic; GA, geographic atrophy Pipeline Leveraging Bioerodible Durasert E™ Drug Delivery Technology Pursuing Large Market Opportuni

  5. Slide 5: Chronic disease treated with short acting anti-VEGFs places significant burden

    Chronic disease treated with short acting anti-VEGFs places significant burden on physicians and patients 77% of Retina Specialists say improved durability is most important when choosing a treatment2. A delay in care/missed visit can result in vision loss A delay in treatment of only 5.34 weeks res

  6. Slide 6: Diabetic Macular Edema: Large Market Opportunity with Significant Unmet Need

    Diabetic Macular Edema: Large Market Opportunity with Significant Unmet Need for More Durable Treatments ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. William R. Rowley, Clement Bezold, Yasemin Arikan, et al. Diabetes 2030: Insights from Yesterday, Today and Future Trends. PubMed Cent

  7. Slide 7: Durasert E: The Next Generation in Sustained-Release Intravitreal Drug Delivery

    Inserts not drawn to scale, for illustrative purposes only. aVitrasert now discontinued. IVT, intravitreal; PEG, polyethylene glycol; PLGA, poly lactic-co-glycolic acid. Durasert E™: The Next Generation in Sustained-Release Intravitreal Drug Delivery Vitrasert® (ganciclovir IVT)a Retisert® (fluocino

  8. Slide 8: DURAVYU: Vorolanib in Bioerodible Durasert E

    *Data from preclinical studies; 1. Bakri SJ, et al. PLoS One. 2024;19(6):e0304782. 2. Patel S, et al. Ophthalmol Sci. Sep-Oct 2024;4(5):100527. 3. Wykoff CC et al. J Vitreoretin Dis. Sep-Oct 2024;8(5):577-586. ANG, angiopoietin; IVT, intravitreal; TIE2, tyrosine-protein kinase receptor TIE-2; TKI, t

  9. Slide 9: DURAVYU Demonstrated Robust Efficacy Outcomes and Excellent Safety Profile

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU™ Demonstrated Robust Efficacy Outcomes and an Excellent Safety Profile Across Multiple Indications BCVA, best-corrected visual acuity; OCT, optical coherence tomography; wet AMD, wet age-related macular degeneration; NPDR, non-prolife

  10. Slide 10: LUGANO/LUCIA Phase 3 Pivotal Trials in wet AMD

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. LUGANO/LUCIA Phase 3 Pivotal Trials in wet AMD NON-INFERIORITY VERSUS ON-LABEL AFLIBERCEPT CONTROL Fully Enrolled

  11. Slide 11: DURAVYU De-Risked Clinical Approach in Wet AMD

    DURAVYU De-Risked Clinical Approach in Wet AMD ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Established FDA approval Path Last four FDA approvals followed the noninferiority pathway On label control arm – patients randomized on Day 1 Completed robust Phase 2 trial Derisked and informed

  12. Slide 12: Positive Phase 2 DAVIO 2 Results in Wet AMD

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Positive Phase 2 DAVIO 2 Results in Wet AMD Support Ongoing DURAVYU Phase 3 Pivotal Program DAVIO2 Endpoint 2mg 3mg R Primary: Non-inferior change in BCVA vs. aflibercept - 0.3 letters - 0.4 letters R Secondary: Favorable safety profile No DU

  13. Slide 13: Phase 3 Pivotal Trials Designed to Evaluate Non-Inferiority vs Aflibercept

    Phase 3 Pivotal Trials - Designed to Evaluate Non-Inferiority of DURAVYU vs On-Label Aflibercept Control ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Screening D1 W4 W8 W12 W16 W24 W32 W84-W92 W20 W28 DURAVYU™ 2.7mg Aflibercept 2mg q8W RANDOMIZATION REQUIRED AFLIBERCEPT INJECTION VISIT

  14. Slide 14: Exceptional Enrollment in Pivotal Phase 3 Wet AMD Program

    Exceptional Enrollment in Pivotal Phase 3 Wet AMD Program Driven by Strong Enthusiasm for the DURAVYU Pivotal Program ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. July 2025 LUCIA enrollment complete (>400 patients)* >800 patients enrolled and randomized across LUGANO and LUCIA January 2

  15. Slide 15: Phase 2 VERONA Clinical Trial in DME

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 2 VERONA Clinical Trial in DME 24 Week results Primary and secondary endpoints achieved DME, diabetic macular edema

  16. Slide 16: DURAVYU Positioned to Provide an Improved DME Treatment Paradigm

    DURAVYU is Uniquely Positioned to Provide an Improved DME Treatment Paradigm Compared to Current Anti-VEGF Therapies ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 24-Month Treatment Regimens for DME: 2–4-month dosing 1-4-month dosing Anti-VEGF SoC DURAVYU™ (vorolanib intravitreal insert)

  17. Slide 17: VERONA: DURAVYU demonstrated stability in vision and anatomical control

    VERONA: DURAVYU demonstrated stability in vision and anatomical control with fewer injections in patients with DME ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU 2.7mg EFFICACY: Primary endpoint met - extended time to first supplemental injection vs. aflibercept control Key second

  18. Slide 18: DURAVYU 2.7mg Improved +10 Letters vs. Baseline at 24 Weeks

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU 2.7mg* Improved +10 Letters vs. Baseline; Nearly +3 Letters Better than Control at 24 Weeks *Data excludes one outlier patient. Outlier patient was removed from analysis because the patient missed multiple visits including the Week 20

  19. Slide 19: DURAVYU 2.7mg Demonstrated Improved Anatomical Control

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU 2.7mg Demonstrated Improved Anatomical Control with 74% More Drying than Aflibercept Control CST: central subfield thickness Source: Independent reading center results available as of the full 24-week data cut. MEAN CHANGE IN CST FROM

  20. Slide 20: Sub-Group of Supplement-Free Patients Had Better Outcomes

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Sub-Group of Supplement-Free Patients Demonstrated Eyes Treated with DURAVYU 2.7mg had Better Visual and Anatomical Outcomes BCVA, best-corrected visual acuity; VA, visual acuity MEAN CHANGE IN BCVA FROM BASELINE +10.3 +3.0 Mean Change in BCV

  21. Slide 21: VERONA Case Study - Rapid Drying with Improved Vision

    VERONA Case Study 1 - Rapid Drying with Improved Vision After Single DURAVYU 2.7mg Treatment and No Supplementation ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Screening BCVA 50 Aflibercept + 2.7mg DURAVYU -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 Day1 1 2 3 4 5 6 Eylea Eylea Vabysmo wash

  22. Slide 22: VERONA Case Study – Better VA and Drying Than Vabysmo

    VERONA Case Study 2 – Better VA and Drying Than Vabysmo After Single DURAVYU 2.7mg Treatment and No Supplementation ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Screening BCVA 72 Aflibercept + 2.7mg DURAVYU -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 Day1 1 2 3 4 5 6 Avastin Vabysmo washout

  23. Slide 23: VERONA: Phase 2 Clinical Trial Summary

    VERONA: Phase 2 Clinical Trial Summary ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Primary endpoint met for both DURAVYU doses Demonstrated rapid and clinically meaningful results without a full load of aflibercept Significant improvement in vision and anatomic results paired with a me

  24. Slide 24: State-Of-The-Art cGMP Manufacturing Facility

    State-Of-The-Art cGMP Manufacturing Facility to Support DURAVYU through Potential NDA Filing and Global Commercial Production ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. cGMP, current good manufacturing practices; FDA, Federal Drug Administration; EMA, European Medicines Agency; cGMP,

  25. Slide 25: On Track for Continued Execution And Well-Funded Through Key Milestones

    On Track for Continued Execution And Well-Funded Through Key Anticipated DURAVYU Milestones ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DME, diabetic macular edema; EOP2, End of Phase 2; wet AMD, wet age-related macular degeneration; SAB, Scientific Advisory Board DURAVYU™ Corporate ✓

  26. Slide 26: Investor Presentation July 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

    Investor Presentation July 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint Pharmaceuticals — Investor Presentation (July 2025) on 6ix